MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.81
-2.61
-4.80%
After Hours: 53.99 +2.18 +4.21% 18:54 03/05 EST
OPEN
55.15
PREV CLOSE
54.42
HIGH
55.34
LOW
43.86
VOLUME
3.21M
TURNOVER
--
52 WEEK HIGH
92.00
52 WEEK LOW
9.18
MARKET CAP
3.51B
P/E (TTM)
-21.5873
1D
5D
1M
3M
1Y
5Y
DJ Intellia Therapeutics Initiated at Outperform by JMP Securities
Dow Jones · 1d ago
DJ Intellia Therapeutics Price Target Announced at $80.00/Share by JMP Securities
Dow Jones · 1d ago
--Analyst Actions: JMP Securities Starts Intellia Therapeutics at Market Outperform With $80 Price Target
MT Newswires · 2d ago
Insider Trends: Intellia Therapeutics Insider Extends 90-Day Selling Trend
MT Newswires · 2d ago
The Intellia Therapeutics (NASDAQ:NTLA) Share Price Is Up 360% And Shareholders Are Delighted
Simply Wall St. · 3d ago
Significant Insider Selling Reported in Shares of Intellia Therapeutics (NTLA)
MT Newswires · 4d ago
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the ...
Insider Monkey · 6d ago
Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4
Zacks.com · 02/26 17:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTLA. Analyze the recent business situations of Intellia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTLA stock price target is 78.46 with a high estimate of 111.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 327
Institutional Holdings: 64.23M
% Owned: 94.84%
Shares Outstanding: 67.73M
TypeInstitutionsShares
Increased
64
5.32M
New
107
5.10M
Decreased
49
5.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Frank Verwiel
President/Chief Executive Officer/Director
John Leonard
Chief Financial Officer/Executive Vice President
Glenn Goddard
Chief Operating Officer/Executive Vice President
Andrew Schiermeier
Executive Vice President/Chief Scientific Officer
Laura Sepp-Lorenzino
Executive Vice President/General Counsel
Jose Rivera
Independent Director
Fred Cohen
Executive Vice President
David Lebwohl
Independent Director
Frederick Cohen
Independent Director
John Crowley
Independent Director
Caroline Dorsa
Independent Director
Jean-Francois Formela
Independent Director
Jesse Goodman
No Data
About NTLA
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.